Active Litigation
Nitrous Oxide Lawsuit Facts
TorHoerman Law is actively accepting claims for the Nitrous Oxide Lawsuit.
Active Litigation
TorHoerman Law is actively accepting claims for the Nitrous Oxide Lawsuit.
A nitrous oxide spinal degeneration lawsuit may involve subacute combined degeneration (SCD) of the spinal cord after repeated recreational inhalation.
Nitrous oxide can disrupt vitamin B12 function, leading to numbness, poor balance, weakness, and difficulty walking in some people.
This condition damages nerve pathways within the cord and differs from age-related disc degeneration.
TorHoerman Law is investigating potential claims involving diagnosed spinal cord injury and allegedly inadequate warnings on nitrous oxide products.

Subacute combined degeneration affects pathways that carry information about vibration and limb position and, in more extensive cases, movement.
Symptoms often develop over weeks or months rather than immediately after one exposure.
Some patients also develop peripheral nerve injury, which can add pain, sensory loss, and weakness to the spinal cord symptoms.
A serum vitamin B12 result may fall within the laboratory reference range even when nitrous oxide has made the vitamin functionally unavailable.
Neurological findings, metabolic tests, and spinal MRI can support the diagnosis, while other causes of myelopathy must still be considered.
Treatment generally involves stopping nitrous oxide use and prompt vitamin B12 replacement, with rehabilitation when needed.
Some patients improve substantially, but prolonged sensory or walking problems have been documented in clinical follow-up.
A potential nitrous oxide lawsuit also depends on identifying the product used, the warnings provided, and evidence connecting the exposure and alleged conduct to the injury.
Subacute combined degeneration is a form of spinal cord injury involving damage to particular nerve pathways within the cord.
The posterior columns carry information about vibration and the position of the limbs, which helps a person maintain balance without watching every movement.
Lateral pathways may also be affected and contribute to weakness or other motor findings.
The term subacute refers to a condition developing over a period of time; combined describes involvement of more than one spinal cord pathway.
Degenerative disc disease involves the structures between vertebrae and can cause nerve compression, but it is a different condition from B12-associated damage within the cord.
The distinction depends on the medical findings, because numbness and difficulty walking can occur in both disorders.
Repeated nitrous oxide exposure can also cause peripheral neuropathy, which affects nerves outside the spinal cord and may occur at the same time as SCD.
Nitrous oxide irreversibly oxidizes the cobalt atom in active vitamin B12, leaving that molecule unable to support B12-dependent processes needed for normal nerve function.
One affected enzyme, methionine synthase, helps convert homocysteine to methionine.
This disruption can raise homocysteine, while another affected B12-dependent pathway can raise methylmalonic acid (MMA).
Abnormal homocysteine and MMA may support functional B12 disruption even when serum B12 appears normal.
Myelin helps nerve fibers transmit electrical signals, so disrupted myelin maintenance can impair sensation, coordination, and movement.
SCD is often described as spinal cord demyelination, while peripheral nerve studies may show axonal loss with or without demyelination; a single blood test cannot establish the full pattern of injury in an individual patient.
A history of recreational use is therefore important, along with the examination, imaging, and consideration of other medical causes.
Clinicians should ask about nitrous oxide exposure when patients report unexplained neurological symptoms, because some people do not initially disclose their use.
Published case series document SCD after repeated recreational nitrous oxide use, often in patients who sought care for impaired balance, weakness, or sensory changes.
These are selected clinical populations, so their findings do not establish the rate of SCD among all nitrous oxide users.
A 2024 study at Royal Perth Hospital reviewed 22 patients with nitrous oxide-related emergency department presentations from June 2019 through June 2021.
Eighteen presented with ataxia, paresthesia, or falls; three had urinary retention or incontinence.
Fourteen underwent MRI because of more severe symptoms, and 12 of those 14 had imaging findings consistent with SCD.
Twenty-one of the 22 patients were admitted to the hospital and all received vitamin B12 treatment, though regimens varied.
The median reported exposure was 150 small bulbs per day over nine months in this group, which reflects heavy use among patients who came to medical attention rather than typical recreational use.
Only four patients were reached for follow-up around three months later; three reported ongoing sensory or mobility problems.
With most patients lost to follow-up, the study cannot establish the long-term outcome for the entire group.
A 2025 study of seven patients with severe nitrous oxide-associated SCD reported posterior-column changes on spinal MRI in every patient.
Six also had evidence of polyneuropathy on electrophysiological testing.
MMA was elevated in all seven, although three had serum B12 concentrations within the normal range.
The five patients assessed at follow-up had improved overall, but each still had some neurological deficits at the last assessment, a median of five months after symptom onset.
This small series shows that a normal serum B12 test cannot rule out functional injury and that improvement does not always mean complete recovery.
It cannot establish the proportion of all affected people who will have permanent symptoms.
SCD may begin with tingling or numbness in the feet or hands and progress to problems with balance and walking.
Damage to position sense can make a person unsteady, especially when visual cues are limited.
Possible findings include:
These findings vary among patients, and paralysis or permanent disability should not be assumed from a diagnosis alone.
Progressive weakness, sensory loss, or walking difficulty after nitrous oxide exposure warrants prompt medical assessment.
Loss of position sense may make walking unsafe even if muscle strength is partly preserved.
Some patients need a cane, walker, or help with daily activities during treatment and recovery.
Continued weakness, falls, or reduced hand coordination can interfere with work, driving, and independent living.
The duration of these limitations depends on the severity of injury and response to treatment; an early examination cannot reliably predict every patient’s long-term outcome.
A neurological examination can identify impaired vibration and position sense, abnormal gait, weakness, or other findings suggesting spinal cord disease.
Clinicians may ask about the amount and duration of nitrous oxide use, prior B12 deficiency, diet, medications, and other medical history.
The workup may include cervical and thoracic MRI, homocysteine or MMA testing, and other tests chosen to rule out alternative causes.
Guidance endorsed by the Association of British Neurologists describes this condition as a clinical diagnosis supported by testing and cautions against delaying treatment while all results are pending.
On T2-weighted MRI, SCD may cause bright, often symmetrical signal in the posterior columns that extends longitudinally through several cervical cord segments.
On an axial image, the pattern can resemble an inverted V.
The finding supports a diagnosis of posterior-column injury but is not unique to nitrous oxide exposure or SCD.
Several disorders can cause similar symptoms or spinal MRI patterns, so the image alone cannot identify the cause.
Other causes of myelopathy, including nutritional deficiency unrelated to nitrous oxide, copper deficiency, inflammation, infection, and cord compression, may require assessment.
An MRI can also appear normal or inconclusive in a patient whose history and examination still raise concern for nitrous oxide-related neurological injury.
Nerve conduction studies may help characterize accompanying peripheral neuropathy when the diagnosis or recovery is uncertain.
A standard serum test measures the amount of circulating B12 but does not show whether the vitamin is functioning normally after nitrous oxide exposure.
For suspected deficiency caused by recreational nitrous oxide use, NICE recommends plasma homocysteine or serum MMA as an initial test.
Those results must be interpreted with clinical findings and potential alternative causes of abnormal levels.
Samples are ideally taken before B12 replacement when feasible, but treatment should not be delayed in a patient with suspected neurological injury while waiting for a test result.
Pernicious anemia, dietary deficiency, and malabsorption may also contribute to B12 deficiency and need consideration in selected patients.
Stopping recreational nitrous oxide exposure is a central part of treatment because continued inhalation can repeatedly inactivate vitamin B12.
The Association of British Neurologists published its clinical practice guidance on February 23, 2023.
The guidance recommends prompt intramuscular hydroxocobalamin for suspected nitrous oxide-induced SCD, with further treatment guided by the patient’s clinical response.
Physical or occupational therapy may help address gait instability, weakness, and difficulty with daily activities.
Patients with repeated use who have difficulty stopping may also benefit from substance-use care.
A vitamin supplement taken while inhalation continues cannot be assumed to prevent neurological injury.
Methionine and folate have appeared in treatment reports, but the guidance does not establish them as routine substitutes for B12 treatment and cessation.
In one case report, symptoms significantly improved after methylprednisolone was added to ongoing B12 treatment when the patient’s condition had worsened.
That sequence cannot establish which treatment produced the improvement, and corticosteroids are not a routine treatment for nitrous oxide-induced SCD.
Yes, some patients regain sensation, balance, and mobility after stopping exposure and receiving B12 treatment.
Recovery can be incomplete, particularly when neurological injury was severe or treatment began after symptoms had progressed.
In the seven-patient Berlin series, all five people evaluated at follow-up retained some deficits despite overall improvement; that selected group does not provide a general probability of permanent disability.
Follow-up may document changes in gait, strength, sensation, and the ability to work or manage daily activities.
The FDA advises consumers not to inhale nitrous oxide from canisters, tanks, or chargers and warns of B12 deficiency, limb weakness, paralysis, and prolonged spinal cord or brain damage.
Its advisory names brands including Galaxy Gas, Baking Bad, Cloud 9ine, Cosmic Gas, and Whip-it!, but naming a brand does not establish that it caused a particular injury or that its manufacturer is liable.
A potential claim may allege that a manufacturer, distributor, or seller failed to provide adequate warnings despite foreseeable recreational inhalation.
Flavoring, canister size, packaging, advertising, sales location, and the actual warnings provided may be relevant to that question.
A product’s culinary use does not by itself settle whether its warnings were legally adequate under the applicable law.
For a claim involving Galaxy Gas or another identified product, its purchase history and labeling may help establish what the person used and which warnings were available.
We are reviewing potential claims involving SCD and other diagnosed spinal cord injuries after recreational nitrous oxide use.
A diagnosis and exposure history are important, but a claim also requires a legally actionable basis against a particular company and evidence connecting that conduct to the injury.
Relevant records and materials may include:
Medical records and product information may address different elements of a claim, including diagnosis, exposure, warnings, and the consequences of the injury.
Preserving available packaging and receipts can help identify the product involved.
Potential personal injury damages may include medical care, rehabilitation, mobility aids, lost income, reduced earning capacity, and pain and suffering where recoverable under state law.
The effect of ongoing sensory loss or difficulty walking on employment and daily life requires documentation specific to the person.
No settlement amount can be predicted from an SCD diagnosis alone; liability, causation, prognosis, and applicable law affect any potential recovery.
The filing deadline varies by state and the type of claim, and gradual onset of symptoms does not automatically extend it.
A discovery rule or other exception applies only when supported by the governing law and facts.
We are investigating potential claims involving SCD and other serious neurological injuries after recreational nitrous oxide use.
The product, its warnings, medical diagnosis, exposure history, and other possible causes all bear on a potential claim.
Call TorHoerman Law today for a free consultation, or use the chat feature to tell us about the injury.
No.
Nitrous oxide-associated subacute combined degeneration affects nerve pathways within the spinal cord, while degenerative disc disease involves the discs between vertebrae.
The conditions can cause overlapping symptoms, so the diagnosis depends on examination, imaging, laboratory findings, and medical history.
Yes.
Nitrous oxide can impair B12 function without reducing its measured serum concentration below the reference range.
In a seven-patient SCD case series, three had normal serum B12, while all seven had elevated MMA.
No.
The MRI pattern can support posterior-column injury but can also occur with other causes of myelopathy.
The exposure history, neurological findings, metabolic tests, and possible alternatives need to be considered together.
Some patients improve after stopping nitrous oxide use and receiving prompt B12 replacement, but complete recovery is not guaranteed.
Persistent sensory changes, weakness, or gait problems have been documented during follow-up in small case series.
A person with diagnosed SCD or another serious spinal cord injury after recreational nitrous oxide use may have a potential claim if the evidence supports product identification, medical causation, and legally actionable conduct.
The diagnosis alone does not establish that a manufacturer, distributor, or retailer is responsible.

Tor Hoerman has represented injured individuals for more than 30 years, with experience spanning individual personal injury cases and nationwide mass tort litigation. His work includes car accidents, catastrophic injuries, product liability claims, and other serious injury cases. Tor has served in court-appointed leadership roles in national litigation and tried cases involving major corporate defendants.
TorHoerman Law’s legal content is researched and written by our editorial team and attorneys for legal accuracy, clarity, and relevance. We rely on statutes, court records, government publications, medical research, and other authoritative sources when applicable. This page provides general legal information and does not constitute legal advice.
TorHoerman Law reviews its legal content for factual accuracy, current information, and relevant legal context before publication and as material developments occur. This article is provided for general informational purposes and does not constitute legal advice. For guidance about a specific case, contact TorHoerman Law.
You can learn more about this topic by visiting any of our Nitrous Oxide Lawsuit pages listed below:
A serious injury can change your life.

TorHoerman Law represents people whose lives have been disrupted by serious injuries, unsafe products, and negligence. Our attorneys handle individual personal injury cases as well as national mass tort lawsuits involving major corporations.
Founded in 2009, our legal team brings more than 100 years of combined experience handling serious injury and complex civil litigation.
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!

In this case, we obtained a verdict of $495 Million for our client’s child who was diagnosed with Necrotizing Enterocolitis after consuming baby formula manufactured by Abbott Laboratories.

In this case, we were able to successfully recover $20 Million for our client after they suffered a Toxic Tort Injury due to chemical exposure.

In this case, we were able to successfully recover $103.8 Million for our client after they suffered a COX-2 Inhibitors Injury.

In this case, we were able to successfully recover $4 Million for our client after they suffered a Traumatic Brain Injury while at daycare.

In this case, we were able to successfully recover $2.8 Million for our client after they suffered an injury due to a Defective Heart Device.
A serious injury can change your life.